Mellas N, Elmesbahi O, Masbah O, Errihani H
Institut national d'oncologie, service d'oncologie médicale, Rabat, Maroc.
Bull Cancer. 2010 Feb;97(2):211-23. doi: 10.1684/bdc.2009.0980.
Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer-related mortality in the world. The combination of chemotherapy and surgery is a standard of care for resectable NSCLC. If the adjuvant chemotherapy is a standard, the role of neoadjuvant chemotherapy is still debated. Most trials of neoadjuvant chemotherapy were closed when the positive studies of adjuvant chemotherapy were published. Only the Spanish trial NATCH, designed to compare the neoadjuvant chemotherapy in the adjuvant chemotherapy, was fully completed. Therefore, the trials of preoperative chemotherapy lack strength to become proof of concept. Confirmation will come from meta-analyses. Two of them are positive. Others are in progress. The current research is to select the patients according to predictive factors to chemotherapy response.
非小细胞肺癌（NSCLC）仍然是全球癌症相关死亡的主要原因。化疗与手术相结合是可切除NSCLC的标准治疗方法。如果辅助化疗是标准治疗，新辅助化疗的作用仍存在争议。大多数新辅助化疗试验在辅助化疗的阳性研究发表时就停止了。只有西班牙的NATCH试验旨在比较新辅助化疗与辅助化疗，该试验已全部完成。因此，术前化疗试验缺乏成为概念验证的力度。确认将来自荟萃分析。其中两项是阳性的。其他的仍在进行中。目前的研究是根据化疗反应的预测因素来选择患者。
